Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - MedPage Today Action Points

ROCKVILLE, Md., Feb. 27 -- The FDA has approved lisdexamfetamine dimesylate (Vyvanse), formerly known as NRP104, for attention deficit hyperactivity disorder.

The amphetamine, to be marketed by Shire, is said to have limited abuse potential, but it was designated Schedule II by the DEA. Shire plc said in a statement that the drug has a lower potential for abuse than other amphetamines used to treat ADHD.

"The label we received with the approval letter includes information about the extended duration of effect and abuse-related drug liking characteristics of Vyvanse, which illustrate benefits that differentiate this compound from other ADHD medicines," said Matthew Emmens, Shire's CEO.

For full article, please visit:

Views: 2


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2020   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service